Compare Fubotv Inc (FUBO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Zoetis Inc — how do they compare? Fubotv Inc trades at $8.92 (market cap $1.02B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 29.6× Fubotv Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Zoetis Inc for 70 Days on average.
| FUBO | ZTS | |
|---|---|---|
Market Cap | $1.02B | $30.20B |
Volume | 978,631 | 6,175,327 |
Sector | Media | Health |
52-Week High | $48.96 | $147.53 |
52-Week Low | $8.09 | $69.09 |
Typical Hold Time | 35 Days | 70 Days |
Enterprise Value | $1.19B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $8.84, down 4.43% today, with bearish technical signals from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and a projected net profit of $123M in 2025. Recent developments include new sports streaming agreements with NHL and TBL Team Boxing League, while analyst consensus remains mixed with 47% buy ratings and a $63.38 price target.
FUBO presents a turnaround story with improving profitability metrics and strategic content partnerships driving growth potential. However, risks include persistent negative cash flow, high debt levels, and intense streaming competition. The stock's current valuation appears attractive with P/E of 2.43 and P/S of 0.19, but execution risks remain significant for investors.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
